Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Balakrishnan, Mini ^a   Yant, Stephen R ^a   Tsai, Luong ^a   O'Sullivan, Christopher ^a   Bam, Rujuta A ^a   Tsai, Angela ^a   Niedziela Majka, Anita ^a   Stray, Kirsten M ^a   Sakowicz, Roman ^a   Cihlar, Tomas ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; NON CATALYTIC INTEGRASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; DIMERIZATION; DNA SYNTHESIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MORPHOLOGY; OLIGOMERIZATION; PHENOTYPE; PROGENY; PROTEIN DNA BINDING; PROTEIN PROCESSING; ULTRAFILTRATION; VIRION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LUCIFERASES; MUTATION; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; VIRION; VIRUS ASSEMBLY; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84883649897     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074163     Document Type: Article

References (55)

1. Pommier Y, Johnson AA, Marchand C, (2005) Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 4: 236-248.
2. Al-Mawsawi LQ, Neamati N, (2007) Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. Trends Pharmacol Sci 28: 526-535.
3. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF, (2008) Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 5: 114.
4. Engelman A, Cherepanov P, (2008) The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog 4: e1000046.
5. Poeschla EM, (2008) Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci 65: 1403-1424.
6. Cherepanov P, (2007) LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res 35: 113-124.
7. Cherepanov P, Devroe E, Silver PA, Engelman A, (2004) Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem 279: 48883-48892.
8. Llano M, Vanegas M, Hutchins N, Thompson D, Delgado S, et al. (2006) Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J Mol Biol 360: 760-773.
9. Turlure F, Maertens G, Rahman S, Cherepanov P, Engelman A, (2006) A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res 34: 1653-1665.
10. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, et al. (2006) An essential role for LEDGF/p75 in HIV integration. Science 314: 461-464.
11. Marshall HM, Ronen K, Berry C, Llano M, Sutherland H, et al. (2007) Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2: e1340.
12. Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, et al. (2006) Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol 80: 1886-1896.
13. Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, et al. (2007) LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 21: 1767-1778.
14. Schrijvers R, De Rijck J, Demeulemeester J, Adachi N, Vets S, et al. (2012) LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog 8: e1002558.
15. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, et al. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359: 355-365.
16. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
17. Shimura K, Kodama EN, (2009) Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 20: 79-85.
18. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201: 814-822.
19. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, et al. (2011) In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55: 813-821.
20. Min S, Song I, Borland J, Chen S, Lou Y, et al. (2010) Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54: 254-258.
21. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, et al. (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6: 442-448.
22. Hu G, Li X, Zhang X, Li Y, Ma L, et al. (2012) Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays. J Med Chem 55: 10108-10117.
23. Tsantrizos YS, Bailey MD, Bilodeau F, Carson RJ, Coulombe R, et al. (2009) Inhibitors of Human Immunodeficiency Virus Replication. International patent application WO 2009/062285 A1.
24. Tsantrizos YS, Bailey MD, Bilodeau F, Carson RJ, Fader I, et al. (2009) Inhibitors of Human Immunodeficiency Virus Replication. International patent Application WO 2009/062289 A1.
25. Tsantrizos YS, Boes M, Brochu C, Fenwick C, Malenfant E, et al. (2007) Inhibitors of Human Immunodeficiency Virus Replication. International patent application WO 2007/131350 A1.
26. Al-Mawsawi LQ, Fikkert V, Dayam R, Witvrouw M, Burke TR Jr, et al. (2006) Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc Natl Acad Sci U S A 103: 10080-10085.
27. Du L, Zhao YX, Yang LM, Zheng YT, Tang Y, et al. (2008) Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase. Acta Pharmacol Sin 29: 1261-1267.
28. Kessl JJ, Eidahl JO, Shkriabai N, Zhao Z, McKee CJ, et al. (2009) An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule. Mol Pharmacol 76: 824-832.
29. Molteni V, Greenwald J, Rhodes D, Hwang Y, Kwiatkowski W, et al. (2001) Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr D Biol Crystallogr 57: 536-544.
30. De Luca L, Barreca ML, Ferro S, Christ F, Iraci N, et al. (2009) Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 4: 1311-1316.
31. Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, et al. (2012) New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 287: 21189-21203.
32. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, et al. (2012) Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 287: 16801-16811.
33. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, et al. (2013) Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A 110: 8690-8695.
34. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R, (1995) Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 69: 2729-2736.
35. Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, et al. (2012) PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrob Agents Chemother 56: 672-681.
36. Cavrois M, De Noronha C, Greene WC, (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20: 1151-1154.
37. Aiken C, (2009) Cell-free assays for HIV-1 uncoating. Methods Mol Biol 485: 41-53.
38. Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, et al. (2012) Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 56: 4365-4374.
39. Forshey BM, von Schwedler U, Sundquist WI, Aiken C, (2002) Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76: 5667-5677.
40. Santos S, Obukhov Y, Nekhai S, Bukrinsky M, Iordanskiy S, (2012) Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology 9: 65.
41. Linde ME, Colquhoun DR, Ubaida Mohien C, Kole T, Aquino V, et al. (2013) The Conserved Set of Host Proteins Incorporated into HIV-1 Virions Suggests a Common Egress Pathway in Multiple Cell Types. J Proteome Res 12: 2045-2054.
42. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, et al. (2005) Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem 280: 25517-25523.
43. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, et al. (2006) Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 80: 11498-11509.
44. Feng L, Sharma A, Slaughter A, Jena N, Koh Y, et al. (2013) The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors. J Biol Chem 288: 15813-15820.
45. Lu R, Ghory HZ, Engelman A, (2005) Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol 79: 10356-10368.
46. Briones MS, Dobard CW, Chow SA, (2010) Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core. J Virol 84: 5181-5190.
47. Zhu K, Dobard C, Chow SA, (2004) Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 78: 5045-5055.
48. Hehl EA, Joshi P, Kalpana GV, Prasad VR, (2004) Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 78: 5056-5067.
49. Challita-Eid PM, Klimatcheva E, Day BT, Evans T, Dreyer K, et al. (1998) Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. AIDS Res Hum Retroviruses 14: 1617-1624.
50. Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43 Pt A: 99-112.
51. Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, et al. (2009) Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 53: 1194-1203.
52. Quan Y, Gu Z, Li X, Liang C, Parniak MA, et al. (1998) Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. J Mol Biol 277: 237-247.
53. Marozsan AJ, Fraundorf E, Abraha A, Baird H, Moore D, et al. (2004) Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol 78: 11130-11141.
54. Butler SL, Hansen MS, Bushman FD, (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631-634.
55. Hung M, Niedziela-Majka A, Jin D, Wong M, Leavitt S, et al. (2013) Large-scale functional purification of recombinant HIV-1 capsid. PLoS One 8: e58035.